What is the 13F Pro Quality Score for APVO?

13F Pro ranks Aptevo Therapeutics Inc. (APVO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View APVO's current score at https://13fpro.ai/research/APVO (free sign-up required for the full ranking).

Where does 13F Pro source APVO data?

All Aptevo Therapeutics Inc. fundamentals and ownership data come directly from SEC EDGAR. Aptevo Therapeutics Inc. files with the SEC under CIK 1671584. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is APVO in?

Aptevo Therapeutics Inc. (APVO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is APVO research updated on 13F Pro?

APVO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Aptevo Therapeutics Inc.(APVO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1671584 APVO stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $33.6M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

APVO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Aptevo Therapeutics Inc. (APVO), a Healthcare sector company. APVO is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $33.6m in revenue. Based on the latest XBRL financial filings (Q1 2026), Aptevo Therapeutics Inc. reports net income of $-6.7M, free cash flow of $-8.0M. Top institutional holders of APVO by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD CAPITAL MANAGEMENT, VANGUARD FIDUCIARY CO, based on the most recent SEC filings. APVO trades on the Nasdaq exchange and files with the SEC under CIK 1671584. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate APVO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aptevo Therapeutics Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-6.7M

Free Cash Flow

Q1 2026

$-8.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY21 $12.3MFY23 —FY24 —FY25 —

Net Income

-7.6% YoY

$-26.0MFY 2025

FY21 $-28.5MFY23 $-17.4MFY24 $-24.1MFY25 $-26.0M

Operating Income

-7.0% YoY

$-26.3MFY 2025

FY21 $-21.4MFY23 $-28.9MFY24 $-24.6MFY25 $-26.3M

EPS (Diluted)

+99.7% YoY

$-87.27FY 2025

FY21 $-6.07FY23 $-2316.83FY24 $-31460.23FY25 $-87.27

Total Assets

+74.4% YoY

$27.2MFY 2025

FY21 $56.6MFY23 $24.8MFY24 $15.6MFY25 $27.2M

Total Debt

—FY 2025

FY21 $27.7MFY23 $0.00FY24 —FY25 —

Op. Cash Flow

-7.6% YoY

$-25.6MFY 2025

FY21 $-21.7MFY23 $-11.7MFY24 $-23.8MFY25 $-25.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2019	FY 2018
Revenue	—	—	—	$12.3M -62.1%	$32.4M +40.6%	$23.1M
Net Income	$-26.0M -7.6%	$-24.1M -38.6%	$-17.4M +38.8%	$-28.5M +29.6%	$-40.4M +24.7%	$-53.7M
Operating Income	$-26.3M -7.0%	$-24.6M +14.8%	$-28.9M -34.9%	$-21.4M +47.8%	$-41.0M +20.7%	$-51.7M
EPS (Diluted)	$-87.27 +99.7%	$-31460.23 -1257.9%	$-2316.83 -38068.5%	$-6.07	—	—
Total Assets	$27.2M +74.4%	$15.6M -37.2%	$24.8M -56.1%	$56.6M +6.0%	$53.4M -20.9%	$67.5M
Total Debt	—	—	$0.00 -100.0%	$27.7M +39.4%	$19.9M +3.0%	$19.3M
Operating Cash Flow	$-25.6M -7.6%	$-23.8M -102.8%	$-11.7M +45.9%	$-21.7M +48.8%	$-42.4M +17.6%	$-51.4M

AI Insight: APVO Financial Trends

Aptevo remains pre-revenue with persistent $6–8M quarterly losses and negative operating cash flow; equity volatile between $-1M and $17M.

• Net income losses ranged $5–8M per quarter over 8 quarters with no revenue reported; operating losses mirrored net losses throughout.

• Operating cash flow deteriorated from $-5M (Q4 2025) to $-8M (Q1 2026), latest quarter showing worst cash burn.

• Equity swung sharply: negative $1M (Q1 2025) to peak $17M (Q3–Q4 2025), then retreated to $12M (Q1 2026).

⚠ No revenue generation across entire 8-quarter window signals continued clinical/development phase with no commercial traction yet.

⚠ Q1 2026 equity decline from $17M to $12M amid $-8M cash burn suggests runway pressure; solvency contingent on financing.

AI Insight: APVO Ratio Trends

Aptevo shows severe profitability deterioration with ROE at -133.6% and ROA at -85.4% in Q4 2025; insufficient data to assess operational trends.

• ROE collapsed to -133.6% in Q4 2025 from -173.6% in Q3 2025, indicating persistent net losses but slight sequential improvement.

• ROA deteriorated to -85.4% in Q4 2025, reflecting severe asset base erosion or substantial operating losses.

⚠ No margin, FCF, or balance-sheet metrics available; cannot assess operational efficiency or leverage trends.

⚠ Consecutive quarters of deeply negative returns signal ongoing cash burn and need to monitor path to profitability.

Get alerted when APVO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Aptevo Therapeutics Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of APVO

GEODE CAPITAL MANAGEMENT, LLC
$56.9K13,337 sh
VANGUARD CAPITAL MANAGEMENT LLC
$54.3K12,713 sh
VANGUARD FIDUCIARY TRUST CO
$17.7K4,142 sh
UBS Group AG
$14.7K3,445 sh
OSAIC HOLDINGS, INC.
$1.5K360 sh
SBI Securities Co., Ltd.
$465.00109 sh
GSA CAPITAL PARTNERS LLP
$84.0019,638 sh
CWM, LLC
$21.005 sh
DANSKE BANK A/S
$4.001 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$56.9K	13,337
VANGUARD CAPITAL MANAGEMENT LLC	$54.3K	12,713
VANGUARD FIDUCIARY TRUST CO	$17.7K	4,142
UBS Group AG	$14.7K	3,445
OSAIC HOLDINGS, INC.	$1.5K	360
SBI Securities Co., Ltd.	$465.00	109
GSA CAPITAL PARTNERS LLP	$84.00	19,638
CWM, LLC	$21.00	5
DANSKE BANK A/S	$4.00	1

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put APVO on your watchlist

Track score changes the day Aptevo Therapeutics Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is APVO a good stock to buy?

13F Pro's AI-powered analysis of Aptevo Therapeutics Inc. (APVO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for APVO are available on the APVO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own APVO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling APVO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Aptevo Therapeutics Inc.'s investment landscape.